We would love to hear your thoughts about our site and services, please take our survey here.
Oncology pipeline - development candidate selected in SMO program for skin cancer - development candidate selected in BTK program for blood cancers and autoimmune diseases - in vivo proof of concept secured in cFMS program for auto-immune diseases - in vivo proof of concept established in Porcupine program for hard-to-treat cancers Post-period - development candidate selected in Porcupine program Anti-infectives pipeline - continued expansion of novel lead series in MRSA program - development candidate selected in MRSA program · Launch of immunology research division in May 2015 - focused on developing new therapies for disorders of the immune system · Cancer research collaboration with Horizon Discovery Group plc, ("Horizon"), the international life science group, focusing on Redx's existing pan-RAF inhibitor program, which treats colorectal cancer, in September 2015 · Group's expenditure remains in line with budgets: - net cash at 30 September 2015: £9.4m (2014: £2.9m) - net loss of £8.2m (2014: £3.4m) - other operating income: £2.6m (2014: £6.2m) · Outlook remains positive Neil Murray, Chief Executive of Redx Pharma Plc, said: "I am delighted with the strong progress Redx has made in this transformational year. Joining AIM has helped us expand our operations, including into immunology research and opens up further opportunities for the business. In our existing research areas in oncology and anti-infectives, we achieved in vivo proof of concept in a further two programs and progressed three drug candidates into formal pre-clinical development. We look forward to building on this success in 2016 as we also look to secure further commercial partnerships and broaden Redx's capability and asset base."
Oncology pipeline - development candidate selected in SMO program for skin cancer - development candidate selected in BTK program for blood cancers and autoimmune diseases - in vivo proof of concept secured in cFMS program for auto-immune diseases - in vivo proof of concept established in Porcupine program for hard-to-treat cancers Post-period - development candidate selected in Porcupine program Anti-infectives pipeline - continued expansion of novel lead series in MRSA program - development candidate selected in MRSA program · Launch of immunology research division in May 2015 - focused on developing new therapies for disorders of the immune system · Cancer research collaboration with Horizon Discovery Group plc, ("Horizon"), the international life science group, focusing on Redx's existing pan-RAF inhibitor program, which treats colorectal cancer, in September 2015 · Group's expenditure remains in line with budgets: - net cash at 30 September 2015: £9.4m (2014: £2.9m) - net loss of £8.2m (2014: £3.4m) - other operating income: £2.6m (2014: £6.2m) · Outlook remains positive Neil Murray, Chief Executive of Redx Pharma Plc, said: "I am delighted with the strong progress Redx has made in this transformational year. Joining AIM has helped us expand our operations, including into immunology research and opens up further opportunities for the business. In our existing research areas in oncology and anti-infectives, we achieved in vivo proof of concept in a further two programs and progressed three drug candidates into formal pre-clinical development. We look forward to building on this success in 2016 as we also look to secure further commercial partnerships and broaden Redx's capability and asset base."
ASHTEAD GROUP PLC - 1st Quarter Results PR Newswire London, August 18 Ashtead Group PLC 18 August 2015 ASHTEAD GROUP PLC Announcement of Q1 Results Ashtead Group plc announces that its first quarter results for the period ended 31 July 2015 will be announced on Tuesday, 2 September 2015.
SENIOR CREDIT FACILITY INCREASED TO $2.6 BILLION AND EXTENDED TO 2020 28 July 2015 Ashtead Group plc ("Ashtead" or the "Company") is pleased to announce that it has amended and extended its $2.0 billion senior credit facility that was due to mature in 2018. The Company has increased the facility size to $2.6 billion, reduced the cost to LIBOR plus 125bps to 175bps and extended its maturity to July 2020. Ashtead's chief executive, Geoff Drabble, commented: "We are delighted to have completed this refinancing which provides us with long term stability and capacity to continue the execution of our well established strategy. It ensures that our debt package remains well structured and flexible. Against a backdrop of strong end markets and market share gains, we will utilise the facility to support the needs of the business with organic fleet growth. This growth combined with further greenfield openings and bolt-on acquisitions will continue to broaden the geographies and markets we serve. We continue to grow responsibly, generating strong returns and maintaining leverage within our stated objectives. I would like to thank the bank group for their support in the further growth and development of Ashtead." ________________________________________________________________________
Followed by RedxPharma. George Osborne ‏@George_Osborne · 2h2 hours ago Great to see work here at @RedxPharma on anti-microbial resistance,a great challenge of our age + one where UK leads pic.twitter.com/V2i3FB5Tk3 Details George Osborne ‏@George_Osborne · 2h2 hours ago Announcing £5m for new Medicines Technologies Catapult on visit to Alderley Park - investing in science key to building #NorthernPowerhouse Details